Zomedica Reports 35% Revenue Growth to $8.8 Million in Q1 2026

Zomedica Corp. reported a significant increase in its financial performance for the first quarter of 2026, with net revenue reaching $8.8 million, a 35% increase from $6.5 million in the same period of 2025. The growth was attributed to enhanced sales from its TRUFORMA® product line, increased consumables sales from existing PulseVet® products, and the commencement of contract manufacturing for Cell-Guardian. The company’s gross profit for the quarter was $5.5 million, resulting in a gross profit margin of 62%, down from 68% in the prior year, primarily due to a shift in product mix.

In terms of expenses, Zomedica reported a total operating loss of $4.9 million, a substantial improvement compared to a loss of $64.5 million in the previous year, largely due to the absence of impairment charges that had significantly impacted the prior year's results. General and administrative expenses decreased by 14% to $5.4 million, while research and development expenses fell by 38% to $1.2 million, reflecting reduced external consulting costs following successful product launches. Selling and marketing expenses also decreased by 24% to $3.8 million, indicating a strategic reduction in discretionary spending.

Operationally, Zomedica's cash and cash equivalents increased to $9.4 million as of March 31, 2026, compared to $9.0 million at the end of 2025. The company reported a working capital of $51.5 million, indicating a solid liquidity position to support ongoing operations. The total employee headcount remained stable at approximately 100, reflecting the company's focus on maintaining operational efficiency while pursuing growth opportunities.

Zomedica's strategic initiatives included the acquisition of Qorvo Biotechnologies, which is expected to enhance its product development capabilities, particularly in the diagnostics segment. The company also entered into a Development and License Agreement with Brisby Inc. to expand its product offerings, including the Smart Pet Pad and Intelligent Pet Bed. Looking ahead, Zomedica anticipates continued revenue growth driven by increased sales and marketing efforts, alongside the successful commercialization of new products.

The company remains cautious about future profitability, as it continues to incur losses, with an accumulated deficit of $304.3 million as of March 31, 2026. Management indicated that while they expect to continue recording net losses in the near term, they are optimistic about achieving sufficient revenue from product sales to offset operating expenses in the future.